Locations
Boston, MA, USA · West Street / River Street, Boston, MA, USA
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
founded in
2017
Leuko is an MIT spin-out developing Point Check™, the first non-invasive white blood cell monitoring device. This innovative technology allows for rapid, portable, and simple testing of white blood cell levels without the need for blood draws, significantly benefiting immunosuppressed patients by enabling more frequent monitoring. By identifying elevated risks of infection, particularly for chemotherapy patients, Leuko aims to improve quality of life and clinical outcomes. The company has received multiple awards and grants, positioning it strongly in the healthcare market as a solution to a critical medical need.
Something looks off?